Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 7/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.36 |
| ▸ | KIF11 | P52732 | 1/20 | 0.36 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.36 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10105627 | 0.82 | PTGS2 (0.43) | PTGS2KIF11AKR1C3AKR1C2 | |
| SCHEMBL13055320 | 0.80 | LMNA (0.42) | PTGS2PTGS1 | |
| SCHEMBL13995391 | 0.80 | KIF11 (0.43) | PTGS2PTGS1KIF11 | |
| SCHEMBL10192308 | 0.77 | KIF11 (0.40) | PTGS2KIF11AKR1C3AKR1C2 | |
| SCHEMBL25974967 | 0.74 | MC4R (0.41) | — | |
| SCHEMBL12686634 | 0.74 | MC4R (0.41) | — | |
| SCHEMBL12686652 | 0.74 | MC4R (0.41) | — | |
| SCHEMBL16437813 | 0.73 | PTGS2 (0.47) | PTGS2PTGS1KIF11 | |
| SCHEMBL13813774 | 0.73 | TSHR (0.39) | — | |
| SCHEMBL10152122 | 0.72 | RORC (0.42) | HTTKIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210122713-A1 | COMPOUNDS, SALTS THEREOF AND METHODS FOR TREATMENT OF DISEASES | ACADIA PHARMACEUTICALS INC. (US) | 2021-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210122713-A1 | COMPOUNDS, SALTS THEREOF AND METHODS FOR TREATMENT OF DISEASES | SLC10A1, VHL, CYP11B2 | PTGS2 1309/4885HTT 320/4885PTGS1 1321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.